Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases that have a remitting, relapsing nature. During relapse, they are treated with drugs and surgery. The present study was based on individual data from patients diagnosed with CD or UC at Herlev University Hospital, Copenhagen, Denmark, during 1991 to 1993. The data were aggregated over calendar years; for each year, the number of relapses and the number of surgical operations were recorded. Our aim was to estimate Markov models for disease activity in CD and UC, in terms of relapse and remission, with a cycle length of 1 month. The purpose of these models was to enable evaluation of interventions that would shorten relapses or postpone future relapses. An exact maximum likelihood estimator was developed that disaggregates the yearly observations into monthly transition probabilities between remission and relapse. These probabilities were allowed to be dependent on the time since start of relapse and on the time since start of remission, respectively. The estimator, initially slow, was successfully optimized to shorten the execution time. The estimated disease activity model for CD fits well to observed data and has good face validity. The disease activity model is less suitable for UC due to its transient nature through the presence of curative surgery.
C rohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases that have a remitting, relapsing nature. Relapses are manifested as increased inflammatory activity and increased symptoms such as abdominal pain, fever, and weight loss. 1, 2 During a relapse, CD and UC are treated with drugs such as oral and topical glucocorticosteroids, 5-aminosalicylates (including sulphasalazine), immunosuppressive drugs (e.g., azathioprine, 6-mercatopurines, methotrexate, cyclosporine), antibiologics (infliximab), and antibiotics, or with surgery. 1, 2 In CD, the most common surgical procedure is resection of a part of the intestine that is severely affected by the disease, in the lack of response to drug therapy. 1, 3, 4 Resection is not a curative treatment and may need to be performed many times because the disease may reappear elsewhere in the intestinal tract. 1 In UC, which by definition only involves the colon, surgery may be considered curative if the entire colon is removed by colectomy, and restorative surgery such as ileoanal pelvic pouch (IAPP) or ileorectal anastomose (IRA) is performed. 1, 4, 5 After such surgery, UC cannot relapse again. However, the patient may suffer complications following IAPP or IRA, namely, inflammation in the pouch or rectum (pouchitis, IRA-proctitis). 4 An intervention aimed at shortening relapses will aim to increase the probability of going from relapse to remission, and interventions to postpone the next relapse (i.e., a more successful maintenance treatment) will decrease the probability of going from remission into relapse. In order to analyze such interventions, a model of remission and relapse is needed. Our aim was to estimate the parameters of Markov models for CD and UC patients who alternate between remission and relapse. In addition, the model needed to run in reasonably short cycles to allow us to study the effect of shortening the relapses.
Our data were partial observations, aggregated over 1-year periods. A translation from the 1-year perspective into a 1-month perspective was required. Translating from long to short intervals of time is fairly simple for a single risk. 6 It is more complicated for transition probabilities in models with several states that allow transition back and forth, that is, transition probability matrices. 6À9 One such method is matrix decomposition, which defines the short-term matrix as a function of the long-term matrix. It determines the short-interval matrix in closed form, that is, using a single formula. 8, 10 However, in some circumstances, the short-interval matrix is an invalid transition probability matrix (e.g., it may contain negative values).
Craig and Sendi 8 demonstrate how the expectationmaximization (E-M) algorithm can be used to approximate the maximum likelihood (ML) in a situation with partial observations, where the algorithm is used to impute data at time points not observed. They demonstrate how this overcomes the problem of invalid short-term matrices. Charitos and others 10 employ matrix decomposition as well, and they use regularization techniques to deal with invalid shortterm matrices. They use their technique to refine an invalid matrix until they find the nearest valid matrix and use that one instead.
Welton and Ades 9 use a Bayesian approach in a similar situation. They present how to estimate transition rates for multistate models from partial data, which consist of observations of the initial state and the state after a certain period of time. Their data are aggregated in the sense that they look at transition counts from groups of patients rather than individual patient data. Once having estimated the transition rates, the transition probabilities are easily obtained for any desired time interval.
Craig, Fryback, and others 11 have observations at uneven intervals (year 1, 5, and 11) of patients with diabetes, where the patients are classified into different stages of retinopathy. Some of the patients are given a treatment intervention at some stage within this range of years. The authors give the transition probabilities a parametric form, and in addition, they add parametric forms for the treatment intervention and for death. Hereby, they manage to estimate the natural history of diabetic retinopathy using a Bayesian approach employing a Markov Chain Monte Carlo (MCMC) technique. 11 These approaches have in common that they have observations of the process at long intervals and try to determine what occurs at time points in between. They all have data on visits to, or transitions between, the states that are of interest. This is different from our situation, as we neither have observations of transitions nor of the patient's state at any point in time. Instead, we have yearly counts of events, namely, the number of relapses, and the number of surgical operations for each patient. We do not know whether they are in relapse or remission at a given point in time, except that they are initially in relapse. Thus our data are not aggregated data from several patients. In our case, each individual patient's events during a year's time are aggregated into summary counts, describing the whole year, for that individual patient. We use the Markov model itself as a framework to produce an estimator of the sought parameters, using the ML method. The ML method estimates its parameter at the value that maximizes the likelihood of observing the actual observations. 12
MATERIALS AND METHODS

Materials
The present study was based on data from patients diagnosed with CD or UC at Herlev University Hospital, Copenhagen, Denmark, from 1991 to 1993 (described in detail elsewhere). 2 The data were organized in calendar years. For each year, the number of relapses and the number of surgical operations were recorded. A relapse is defined as a contact with a physician due to gastrointestinal symptoms that led to increased use of medication or surgery. 2 The year was classified according to a disease course level: silent, mild, and severe. A silent year is a year completely in remission. A mild year has 1 to 2 relapses but no surgery. A severe year has more than 2 relapses, or presence of surgery, or both. This is a simplified definition of disease course which aims to resemble earlier definitions of annual classifications of disease activity 3, 5 and which will be clinically correct for most situations. There are clinical situations where a discrepancy may occur; for example, a whole year with continuous severe symptoms would be classified as a mild year with 1 relapse here but would be regarded as a severe year clinically. The types of surgery recorded in the database were total and subtotal colectomy, small intestine resection, colon resection, and ''other,'' such as fistula surgery or stricture plastic.
A total of 145 individuals, of whom 58 were diagnosed with CD and 87 with UC, were observed for a total of 1292 patient-years ( Table 1 ). The CD patients had average rates of 0.60 relapses per year (range, 0-5 relapses) and 0.24 surgical operations per year (range, 0-5 procedures) ( Table 2 ). The UC patients had 0.69 relapses per year (range, 0-7) and 0.04 surgical operations per year (range, 0-4).
Methods
Our data consist of yearly observations of the number of relapses and the number of surgical operations that the patient has experienced within the year. The notation used to describe the data is as follows. We observe an individual i for n i years and the number of surgical operations Z i = (Z i1 Z i2 . . . Z in i ) and the number of relapsesV i = (V i1 V i2 . . . V in i ) during each observed year. As an example, one particular patient was observed during 11 years, of which the first 2 contained 1 relapse each. During the second year, the patient was subjected to 2 surgical operations. The disease was silent from the third year and on, with no new relapses or surgery. Thus, n i = 11, V i = ð1,1,0,0,0,0,0,0,0,0,0Þ, and Z i = ð0,2,0,0,0,0,0; 0; 0; 0; 0Þ.
A Markov model was constructed for the disease activity in CD and UC. We developed an exact ML estimator for the parameters of this model. 12, 13 The ML estimator uses the probability of observing the actual observations conditionally on the parameter vector. By selecting the parameter values so that the probability is maximized, estimates of the parameters are obtained. Sometimes, it is possible to derive the estimator in closed form. Otherwise, the parameter values are found using a numerical search. To avoid finding just local maxima, several starting points are used. We used 20 starting points. The estimator was used to transform the yearly data into monthly probabilities. We tried to determine whether the estimated disease activity models could successfully predict disease course and whether the estimator appeared to work and how accurate its estimates were. The model, estimator, and our approach to judge its success are described in the following sections.
Disease Activity Model
The disease activity model is a Markov chain, S t , t = 0,1,. . ., with 4 states, first month of remission (S t = 1), subsequent months of remission (S t = 2), first month of relapse (S t = 3), and subsequent months of relapse (S t = 4), which is presented in Figure 1 . The transition probability matrix is the following: where p 1 , p 2 , p 3 , and p 4 are the transition probabilities (p 1 from state 3 to 1, p 2 from state 4 to 1, p 3 from state 1 to 3, and p 4 from state 2 to 3). These 4 transition probabilities and p 5 , the probability of surgery while visiting state 3 or 4, are the 5 parameters to the model which we aim to estimate. Time dependence is restarted for each new visit to remission and relapse. The relapse states form a 2-state tunnel. A consequence of this construction is that we can easily model a mixture of short and long visits to, for example, relapse, say p 1 = 1=2, p 2 = 1=5 would make half the visits 1 cycle long and the remainder (conditional on having stayed the first month) geometrically distributed with a mean duration of 5 cycles, that is, 5 months. The remission states form the same construction, with its own parameters. Our model is the minimal Markov model that has timedependent probabilities of changing from remission to relapse and vice versa. The probability of relapse (and remission, respectively) is dependent on the time since entry into remission (and into relapse, respectively) as this is embedded in the model structure, but the Markov model itself is time homogeneous because no parameter value (p 1 , p 2 , . . . , p 5 ) will change over time.
Along with the Markov chain, S t , t = 0,1, . . ., we use a surgery indicator T t , t = 0,1, . . . whether the patient was subjected to surgery while visiting state 3 or 4, that is, PrfT t = 1g = p 5 if S t = 3 or S t = 4, and 0 otherwise.
The disease course of a 12-month sequence of disease activity fðS t , T t Þg; t = 1,2, . . . , 12 is determined according to the definition given above. If fT t = 1g for any t = 1,2, . . . , 12, or if there are 3 or more visits into the relapse states, the disease course is severe. If there are 1 or 2 visits into the relapse states and fT t = 0g for all t = 1,2, . . . , 12, the disease course is mild. In case of no visits to the relapse states, the disease course is silent.
A relapse in the model begins with a transition into state 3, possibly followed directly by 1 or more cycles spent in state 4. The relapse ends with a transition to state 1. A relapse beginning one year and lasting into the next year contributes to the relapse counts in both years.
The disease activity Markov chain has the following stationary distribution:
where p 2 > 0, p 4 > 0. We assume that this stationary distribution and our disease activity model are relevant during the period when the patients were observed.
Exact ML Estimator
The likelihood for an individual i is L i ðyÞ = PrfZ i = z i , V i = v i |yg, a function of the disease activity model parameters y = p 1 p 2 p 3 p 4 p 5 ð ). The probability of the observations during a given year l and the disease activity as the next year begins (S 13 ), conditionally on the disease activity at its beginning (S 1 ) and y, is denoted by the following:
where I 1 ðtÞ = Ift 1 + t 2 + Á Á Á + t 12 = z l g, and I 2 ðsÞ = Ifvðs 1 , s 2 , . . . , s 12 Þ = v l g. The summation goes over all possible sequences of fS r g 12 r = 2 and fT r g 12 r = 1 . The indicators select those sequences, which have z l surgical operations and v l relapses, respectively. The indicator of sequences that have v l relapses cannot be given explicitly, but it indicates whether the number of visits into the group of states 3 and 4 as described above is equal to v l . The last term is the probability of the sequences fS r g 12 r = 2 and fT r g 12 r = 1 , and this probability is a product of elements in the disease activity transition probability matrix (P s 1 , s 2 is the 1-month probability of transition from s 1 to s 2 ) and of the probabilities of a set of Bernoulli trials:
This probability will become zero for many of the sequences S t whenever one or more of the corresponding transition probabilities (P s 1 , s 2 ) are zero.
Then, we can write the likelihood for an individual's observed sequence by counting over all possible disease activity (S i, l,1 ) at the beginning of each year, l = 1,2, . . . , n i + 1 (including the final target state):
The first part is a series of matrix multiplications. The last factor, the probability of the initial state, is taken from the stationary distribution p. Because we know that the patients start with a relapse, S i, 1,1 must be 3 or 4. Conditionally on this, we get PrfS i, 1,1 = jg = p j =ðp 3 + p 4 ).
An ML estimate was sought by maximizing the product of all the individuals' likelihoods LðyÞ = Q i L i ðyÞ with regards to y. This process is very time consuming because the probabilities y s, u ðz, v) were computed exactly by traversing every possible sequence of disease activity.
However, the structure of the model never changes. Each possible pathway through the model is a product of the probabilities p 1 , p 2 , . . . , p 5 and their complementary probabilities. Therefore, equation 1 can be rewritten using a set of exponents a 1 , b 1 , . . . , a 5 , b 5 :
The exponents a 1 , b 1 , a 2 , b 2 , a 3 , b 3 , a 4 , and b 4 are the number of times that p 1 , (1 − p 1 ), p 2 , (1 − p 2 ), p 3 , (1 − p 3 ), p 4 , and (1 − p 4 ), respectively, occur as factors in the probability expression. They are determined for each pathway through the model. The last 2 exponents are taken directly from equation 1, a 5 = P
g . Not all sequences S t and T t generate unique sets of exponents. We define a profile to be the set of numbers s 1 , s 13 , a 1 , b 1 , a 2 , b 2 ,. . ., a 5 , b 5 , v, r that describe the r sequences with v relapses and a 5 surgical operations that begin with S 1 = s 1 and end with S 13 = s 13 and that all have a probability that can be described with the exponents a 1 , b 1 ,. . ., a 5 , b 5 , as shown above. Reducing the pathway to such exponents results in loss of information on the number of relapses. This is therefore recorded in the profile as v.
Therefore, we can determine y s 1 , s 13 ðz, v) by summation over all relevant profiles:
where the sum is taken over all profiles that have v relapses and z surgical operations, and the suffix j is used to illustrate the values that are specific to each such profile. For the sake of effective computation, we traverse the whole set of profiles once for each value of y and aggregate the probability of each profile into the corresponding y s 1 , s 13 ðz, v); that is, we compute these probabilities for all combinations of values of z and v simultaneously. This method is used to compute the likelihood. The complete set of profiles can be prepared in advance, and this means that some of the time-consuming work is performed just once. In addition, because there are fewer profiles than unique pathways through the model, the amount of work that is performed during the ML estimation is less using profiles.
Goodness of Fit of the Estimator
We used the estimated models to simulate disease activity in each model for a period of 10 years for as many patients as we had in the input data. For each patient, each year was classified into disease course levels according to relapses and surgery experience. This predicted disease course was compared to the observed disease course from the 147 patients ( Table  1) . The predicted disease course should be similar to the observed disease course.
A validation of the estimator itself was performed using the above-described procedure backwards. Using known parameter values, we simulated the model and created a number of exercise dataset, with number of relapses and number of surgical operations per year for each individual. The ML estimator was then used on these datasets to estimate the parameters used for simulation. The residuals between the estimated parameter values and the original (true) parameter values were computed across all training datasets. This was done both for the probabilities in the model and for the mean length of stay in remission and relapse, which are functions of the probabilities.
Uncertainty in Estimates
We used bootstrap analysis to address the uncertainty in the parameter estimates. 14 The original dataset was replicated by resampling the patients along with their corresponding disease history data. This yielded a set of replicated parameter vector estimates which was used to estimate variation and confidence intervals. To use the bootstrap results in a stochastic evaluation of the model, one could sample whole parameter vectors from the set of replicates, so that the dependencies between the parameters are kept intact. 15 
Software Tools
The ML estimator was implemented as a package in the R language and environment for statistical computing, 16 with some components written in the C language. 17 The package can be obtained from the corresponding author. The bootstrap analysis used the boot package for R. 18, 19 
RESULTS
The estimated model parameters p 1 , p 2 , . . . , p 5 for CD and UC are presented in Table 3 . The probabilities of remission, p 1 , p 2 , are quite different, about twice as high during the first month (0.63) as during the following months (0.33), in CD. The difference is about 7 times in UC (0.81 during the first month, and 0.12 during the following months). The different probabilities mean that the probability of remission declines over time, as expressed in time since start of relapse. The probabilities of relapse, p 3 , p 4 , are similar between CD and UC, with quite a large difference between the first and following months (0.40 v. 0.023 in CD; 0.49 v. 0.022 in UC), also here demonstrating a time dependence, with probabilities that decline over time since start of remission. The probability of surgery, per month in relapse,p 5 , is 0.19 in CD and 0.023 in UC.
The mean length of stay in remission in the model for CD is 27.6 months; however, the length of stays is skewed with a median of 9 months, which was estimated from simulation using the point estimates presented above. The mean length of a relapse is 2.1 months, and the median is 1 month. Using the first month of relapse (i.e., state 3 as shown in Figure 1 ) as a starting point, a patient is expected to suffer 1.8 relapses including the initial one (95% confidence interval [CI], 1-4 relapses) and spend a total of 2.7 months in relapse and 9. c. These are probabilities of remission (P 1 , P 2 ), probabilities of relapse (P 3 , P 4 ), and probability of surgery in the relapse states (P 5 ). See also Figure 1 .
In the model for UC, the mean length of stay in remission is 24.5 months; however, the length of stays is very skewed with a median of 2 months. The mean length of a relapse is 2.7 months, and the median is 1 month. The 75% quantile of the relapse length of stay is 1 month too, so most stays in relapse last for just 1 month. With a starting point as above, a patient is expected to suffer 2.0 relapses including the initial one (95% CI, 1-5) and spend a total of 3.1 months in relapse and 8.9 months in remission (95% CI, 0-12) during a 1-year time frame. The expected number of surgical operations would be 0.072 during this period of time. The width of the 95% CI for total time in remission indicates that there is a very large variation between the patients in this model (c.f. Discussion). The long-term rates are 0.55 relapses per year and 0.004 surgical operations per year.
Goodness of Fit of the Estimation Model
We used our estimated models to simulate disease activity in each model for a period of 10 years, aggregated this over individuals and calendar years, and compared it to the observed disease course (Figure 2) .
For both diseases, there is an initial spike in severe and mild. Then, the disease course appears to go into a fairly steady state. In the observed disease course, the spike comes from patients getting the disease, and the steady state follows as the patients come under treatment. To model this, we use relapse as the starting point when predicting the disease course.
For CD, the similarity is good. For UC, the predicted disease course is still similar to the observed, but there is a decline in severe and mild in the observed disease course that does not appear in the predicted disease course (c.f. Discussion).
We also performed a validation of the estimator itself by looking at residuals between estimated parameter values and the true parameter values when these were known in a number of exercise datasets of the same size as the CD dataset. For the probability estimates, the mean residual was -0.03 (SD, 0.09). Using the probabilities to predict the mean length of stays in remission and relapse, the mean residual of the length of stay estimates was −0.4 (SD, 1.6) months.
Uncertainty in Estimates
The dataset for CD was bootstrapped to estimate SD and CIs for the parameters and for the duration of remission and relapse ( Table 4 ). The bootstrap means of p 1 and p 2 are somewhat different than the original estimates (Table 3) , but p 3 , p 4 , and p 5 are very similar. The SDs of the probability estimates are in the range of 0.003 to 0.14. The bootstrap mean duration of remission is 29.9 months, and duration of relapse is 2.3 months (SD, 9.5 and 1.9, respectively), which is slightly higher than the original means. A 95% CI for the mean duration of remission is 22 to 57 months (relapse, 1.6-3.0 months).
DISCUSSION
In this article, we have presented an ML estimator for a situation where patients have been observed indirectly through disease history aggregated over yearly observation periods. We estimated an underlying Markov model by disaggregating the data and simultaneously rescaling time into a 1-month model cycle. The main part of our problem is to disaggregate our data, and as it is accomplished, the translation into shorter intervals comes automatically. Disaggregation and time translation are done by the same methodology. The translation from a long observation interval into a shorter perspective has been previously addressed. 8À11,15 Matrix decomposition only solves part of our problem that is to translate into a shorter interval of time. The E-M algorithm could in principle be employed to disaggregate our data, but where Craig and Sendi use the E-M algorithm to impute values between their observations, we would need to use the algorithm to impute the entire disease history for every patient. Another possibility would be to do a parametric or semiparametric formulation of the transition probabilities 11, 15 and manipulate the probabilities directly to obtain a good fit to the data. However, like with the E-M algorithm, having to rely on data on disease history aggregated over time imposes a practical problem of disaggregation which we judge to be impractical using this approach.
We examined our ML estimator using training datasets, which indicates that it works with data simulated from our particular estimation model. The model allows the probability of remission to depend on time since start of relapse and the probability of relapse to depend on time since start of remission. In simulated training datasets with time dependence embedded into the model structure in this way, the resulting estimates pick this up. Likewise, in training datasets without such dependence, the estimator usually gives estimates that do not show this dependence. This shows internal consistency of the estimator.
The estimator was optimized to improve execution time. We cannot isolate the time savings from the profiles method presented above, but the overall optimization of the estimator, where the profiles provided a substantial part of the time savings, reduced the time to arrive at an estimate of about 3 hours down to about 1 minute, using a computer with an Intel Core Duo processor T2400 (1.83 GHz) (Santa Clara, CA) running Windows (Microsoft, Redmond, WA). The execution time applies to each one of the starting points for the numerical search, so the impact of optimization is considerable. For the whole work in total, the estimation took a couple of hours of effective time, and the bootstrap analysis took about 8 hours. Craig and Sendi 8 demonstrate how another method, the E-M algorithm, can be used for difficult estimation problems. Because they do not give any indications on the performance of their estimator and because their approach applies only to a part of our problem, we cannot compare the execution times. They use the E-M algorithm to impute values at a few time points between their observations, whereas our situation with aggregated data would require imputation of the entire process of every patient. Therefore, the E-M algorithm appears unwieldy for our situation with partial data aggregated over time. Craig and Fryback use an MCMC approach to impute unobserved values. Their estimator used 48 CPU hours on an IBM RISC/ 6000 computer (Armonk, NY), after which it had produced a complete posterior distribution of the model parameters. This is a long time on a huge computer, but the full posterior distribution is also very useful and complete.
Early attempts with a very simple disease activity model, with just one relapse state and one remission state, failed to fit to the given observations. Such a model has a very low probability of seeing the frequencies of silent, mild, and severe patient-years such as in Table 1 ; they would instead be concentrated to just 1 of the 3 categories. This was the reason for splitting the relapse and the remission into a first month state and a state for the following months, respectively, allowing for the time dependence described above. Furthermore, the choice of model structure excluded death. UC does not appear to have any excess mortality, while CD has some. 2 We have assumed that the end of a patient's observation period was noninformative for the disease activity, regardless of cause. It was our judgment that this would not affect the disease activity model if used with reasonably short time frames.
Our exploration of the goodness of fit of the estimated models against the observed data indicates that our estimator works fairly well also on the real dataset, at least for CD. Although our definition of disease course is simplified, it is used both for the predicted data and for the observed data so the validation is unaffected, and we believe that the deviation from the clinically correct definition has a very minor impact. The bootstrap analysis resulted in fairly wide CIs for some parameters, but this could be due to patient heterogeneity and by the relatively little information available for the estimator. Silverstein and others 20 estimated a Markov chain for CD by mapping patients into disease states over time according to detailed longitudinal medical records. They defined their disease severity states according to type of medical or surgical therapy and by the patients' response to medical therapy. In particular, relapse was split into 4 states (drug-responsive, drug-dependent, drug-refractory, and surgery), and remission was split into remission and postsurgery remission. Therefore, a direct comparison cannot be made because our disease states do not match theirs. However, we can make an approximate comparison to validate our model. They saw a median (75th percentile) stay in remission of 4 (19) months and 26 (76) months in postsurgery remission. Our remission state encompasses both, and our estimate of the median duration falls in between to 9 months (39 months). Silverstein estimated the median duration of relapse to 1.4 to 2.7 months, unless the patient was drug dependent (7.7 months). Our estimated median was 1 month (75th percentile, 2 months), so it was a little shorter. Silverstein and others used data that did not require any translation and included a total of about 1900 patient-years of observations compared to our 514, so they were less affected by censoring in states of long duration and should have less uncertain estimates. This might contribute to why our estimate in remission is much lower than their estimate of the duration in postsurgery remission. We believe that the remaining discrepancies are explained by the different disease state definitions. Our disease activity model was designed primarily with CD in mind. UC is different because surgery methods exist that will end the disease activity. After colectomy, UC cannot relapse. However, pouchitises and IRA-proctitises can occur, so our relapsing and remitting model of UC could still be fairly valid as long as we define relapse as UC relapse, pouchitis, and/or IRA-proctitis. An important question is whether the way UC relapse occurs before colectomy and the way pouchitis/proctitis occurs after colectomy are similar enough from a stochastic point of view. Our Markov model and the corresponding ML estimator have time-homogeneous transition probabilities. Any change in the behavior of the patients in connection to a colectomy would violate this underlying assumption. Indeed, we see a very surprising estimate of the duration of remission in UC, a mean of 24.5 months and a median of just 2 months. From a clinical point of view, such a short median duration is unrealistic. The distribution of the duration in the estimated model is skewed with a very heavy tail, which explains the wide CI for the time spent in remission. The goodness of fit test of predicted against observed disease course ( Figure 2) shows an initial spike and a fairly stable long-term distribution. Initially, when the disease is active and the patient is diagnosed, there are no patients in remission. This is handled by the estimator by using relapse as the starting state. In the long term, CD shows a fairly level distribution of remission, mild and severe, which we interpret as observing a steady state with some noise. Thus, we see no signs of violation of the time-homogeneous assumption in CD during the observed time period. In UC, however, there is seemingly a growing proportion of patients in remission over time, that is, a sign of time-inhomogeneous probabilities of relapse and remission. This is not visible in the predicted disease course and should not be because the disease activity model is time homogeneous.
Thus, we believe that UC due to its transient nature is not very well modeled by our disease activity model.
The predicted rates of relapse and surgery are initially high due to the starting point in relapse and become lower in the long term. The observed average rates fall in between, which should be expected as they represent a mixture of the initial and longterm rates. We believe that the relation between the predicted and observed rates is reasonable.
In our disease activity model, there is no connection between surgery in relapse and a quick return to remission. Not capturing this dimension is a weakness of our model. Surgery could be embedded into the model structure to solve this problem, but that would make the ML estimator more complicated, and we know from experience that the evaluation time of the estimator would be very long. Another aspect of surgery is that a UC patient could in real life have a colectomy with stomia during relapse and elective pouch surgery in a subsequent period of remission, that is, a 2-session surgery. 1, 4 This is entirely impossible in our model because we tie all surgery to relapse. This limitation to our model gives rise to additional doubt to whether it is suitable for UC. These aspects on surgery and also the overall transient nature of UC through its curative surgery option would require a further developed disease activity model with its own estimator. The increased complexity of such a model would make the estimator much slower, imposing a strong practical limitation. However, after successful optimization, the impact would be considerably less, and this could be attempted in a future study.
Our aim to develop a model in which a hypothetical intervention effect could be explored appears to have been met, at least for CD. We established a link from the observed annually aggregated data to a model with 1-month cycles, which we could verify. This model represents the mix of treatment options in use during the observation period. A novel intervention could be compared to the standard care given by this mix by modifying the model parameters. To explore the value of, say, shortening relapses by some amount, one would modify the probabilities of remission accordingly. By assigning unit costs and appropriate effectiveness measures, for example, QALY weights, to each state, the costs and QALYs could be estimated with or without this intervention, and a cost-effectiveness analysis could be performed. The uncertainty surrounding the model parameter estimates could be incorporated based on the bootstrap analysis as outlined above.
